Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ocugen Receives Orphan Drug Designation from FDA for OCU410ST aimed at treating ABCA4-associated retinopathies, including Stargardt disease, Retinitis Pigmentosa 19, and Cone-Rod Dystrophy 3. This designation highlights the potential of OCU410ST to address a significant gap in treatment options for the approximately 44,000 patients in the U.S. affected by these conditions. The gene therapy utilizes an AAV delivery platform to administer the RORA gene, which plays a crucial role in retinal health. Ocugen plans to submit an IND application in Q2 2023 to start a Phase 1/2 clinical trial, furthering their commitment to innovative treatments in rare retinal diseases.
Ocugen, a biotechnology firm focused on innovative therapies, announced that its CEO, Dr. Shankar Musunuri, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, from 11 a.m. to 11:30 a.m. EDT. The event will be held at the Nasdaq Market Site in New York City.
Dr. Musunuri will discuss the company's advancements, including positive results from the ongoing OCU400 Phase 1/2 trial, and outline expected milestones. Investors can also schedule one-on-one meetings with Ocugen's leadership team during the conference.
A live video webcast of the discussion will be available on Ocugen's investor site.
MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Ocugen (NASDAQ: OCGN) is set to present its innovative modifier gene therapy platform at the ARVO 2023 Annual Meeting from April 23-27, 2023. The therapies include OCU400, targeting retinitis pigmentosa and Leber congenital amaurosis, OCU410 for dry age-related macular degeneration (dry AMD), and OCU410ST for Stargardt disease, along with biomolecule OCU200 for diabetic macular edema (DME). Following positive Phase 1/2 trial results for OCU400, Ocugen aims to share its advancements in treating complex retinal diseases affecting millions globally. Key presentations by Ocugen team members are scheduled throughout the conference, providing crucial insights into their ongoing research and development efforts.